Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade

Hemab Therapeutics (NASDAQ:COAG) shares recently hit a new 52-week high of $54.19 following an analyst upgrade from HC Wainwright, which raised its price target to $60 and maintained a Buy rating. The company holds a "Moderate Buy" consensus from analysts with an average price target of $51.40. Despite a recent quarterly loss missing analyst estimates, major shareholder RA Capital Management increased its stake, signaling continued confidence in the biotechnology firm.